This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

N. G. McElvaney, MB, BCh, MRCPI; P. G. Wilcox, MD, FRCPC; A. Churg, MD, PhD; J. A. Fleetham, MB, BS, FRCPC

Arch Intern Med. 1988;148(10):2231-2236.

Abstract
• Pleuropulmonary disease has been observed in eight patients with Parkinson's disease treated with bromocriptine or Its related compound, mesulergine. The pleuropulmonary changes included pleural effusions, pleural thickening, and parenchymal lung disease. The patients developed symptoms from nine months to four years after starting treatment with bromocriptine that varied in dosage from 22 to 50 mg daily, while the patient receiving mesulergine was taking 6 mg daily. No other cause was found for the pleuropulmonary changes. In six patients the medication was discontinued with subsequent clinical, physiologic, and radiologic improvement. In two patients bromocriptine treatment was continued for one to two years, and in one patient there was further physiologic and radiologic progression of the pleuropulmonary changes. These findings suggest a causal relationship between bromocriptine treatment and pleuropulmonary disease. We recommend a chest roentgenogram and pulmonary function evaluation prior to bromocriptine treatment with follow-up studies If the patient develops respiratory symptoms. Physicians prescribing bromocriptine should be aware of this side effect to ensure early recognition and prompt withdrawal of bromocriptine therapy.

(Arch Intern Med 1988;148:2231-2236)

Author Affiliations
From the Departments of Medicine (Drs McElvaney, Wilcox, and Fleetham), and Pathology (Dr Churg), University Hospital, Vancouver, British Columbia.

Footnotes
Accepted for publication May 24, 1988.

Reprint requests to Department of Medicine, Respiratory Division, University Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5 (Dr Fleetham).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-Term Management of Prolactinomas
Schlechte
J. Clin. Endocrinol. Metab. 2007;92:2861-2865.
ABSTRACT | FULL TEXT  

Bromocriptine treatment of systemic lupus erythematosus
Walker
Lupus 2001;10:762-768.
ABSTRACT  

Drugs and the Pleura
Morelock and Sahn
Chest 1999;116:212-221.
ABSTRACT | FULL TEXT  

Treatment of Parkinson's Disease
Calne
NEJM 1993;329:1021-1027.
FULL TEXT  

Bromocriptine and Pleuropulmonary Disease
MELMED and BRAUNSTEIN
Arch Intern Med 1989;149:258-259.
ABSTRACT